-
1
Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis
Published 2025-05-01Subjects: Get full text
Article -
2
CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma
Published 2024-12-01Subjects: “…CD20…”
Get full text
Article -
3
Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients
Published 2025-02-01Subjects: Get full text
Article -
4
Lymphoma patients treated with anti-CD20 and chemotherapy display disconnected T and B cell responses to COVID-19 vaccine
Published 2025-01-01Subjects: Get full text
Article -
5
Preventing Severe COVID-19 with Tixagevimab-Cilgavimab in Hematological Patients Treated with Anti-CD20 Monoclonal Antibodies: An International Multicenter Study
Published 2024-12-01Subjects: “…Anti-CD20…”
Get full text
Article -
6
The Role of the New Anti-CD20 Monoclonal Antibodies in Active Relapsing – Remitting Multiple Sclerosis Treatment: Efficacy and Safety of ofatumumab
Published 2024-03-01Subjects: Get full text
Article -
7
Infiltration and subtype analysis of CD3 + CD20 + T cells in lung cancer
Published 2025-01-01Subjects: Get full text
Article -
8
New T-lymphocyte subpopulations and their characteristics: Challenges to the classical division of lymphocyte function
Published 2024-11-01Subjects: Get full text
Article